Acceleron  

CORPORATE PROFILE

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company’s lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases, myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.

The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our product development strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, clinical trials and objectives of management and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates", "may", "project", "will", "would", "could" "should", "target", "continue", "intend" and similar expressions. There are a number of important factors that could cause Acceleron Pharma's actual results to differ materially from those indicated by such forward-looking statements, including the outcome of our preclinical testing and early clinical trials may not be predictive of success of later clinical trials and interim results of such clinical trials do not necessarily predict final results, the clinical drug development of our therapeutic product candidates involves a lengthy and expensive process, with an uncertain outcome, and we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our protein therapeutic product and other factors identified in the "Risk Factors" section in our filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.